Korea University Researchers Revive NK1 Receptor as Depression Target Through Novel Molecular Design
Key Insights
Korea University researchers have demonstrated that redesigning the molecular structure of NK1 receptor antagonists (search) can restore antidepressant effects in preclinical models after decades of failed clinical trials.
Using machine learning-based virtual screening, the team identified structurally distinct NK1R (search) antagonists that lack the 3,5-bis-trifluoromethylphenyl group found in earlier failed drug candidates.
Lead compound #15 (search) reduced depressive-like behaviors and neuroinflammation (search) in mouse models of stress- and inflammation-induced depression (search) without affecting locomotor activity.
Researchers from Korea University have revived the neurokinin-1 receptor (search) (NK1R (search)) as a potential therapeutic target for major depressive disorder (search), demonstrating that structural modifications to antagonist compounds can restore antidepressant effects in preclinical models. The study, led by Professors Hyeijung Yoo, Hong-Rae Kim, and Hyun Kim and published in Experimental & Molecular Medicine on November 28, 2025, suggests that decades of clinical failures may have stemmed from chemical design limitations rather than biological inadequacy of the target.
Overcoming Historical Setbacks
For years, the NK1 receptor appeared promising as an antidepressant target due to its involvement in stress and emotional regulation. However, optimism diminished after several high-profile clinical trials failed to demonstrate consistent benefits. Drugs such as aprepitant, despite promising early experimental evidence, did not meet expectations in patients, leading many researchers to question the viability of NK1R (search) as an antidepressant target.
The Korea University team hypothesized that the failure may not have been due to the biology of the target itself, but rather the chemistry of the drugs designed to act on it. Earlier drug candidates frequently shared a chemical feature known as the 3,5-bis-trifluoromethylphenyl (TFMP) group, which the researchers suspected may have contributed to inconsistent clinical outcomes.
Machine Learning-Guided Drug Discovery
Rather than abandoning NK1R (search), the researchers focused on redesigning the structure of compounds used to block it. The team employed machine-learning-based virtual screening, analyzing millions of molecules to find NK1R antagonists that lacked the TFMP group. By removing this common structural element and replacing it with a structurally distinct scaffold, the researchers identified new NK1R antagonists with markedly different properties.
Several promising compounds were synthesized and tested in animal models, with one molecule, referred to as compound #15 (search), emerging as particularly effective. In mouse models of stress-induced and inflammation-induced depression (search), the compound reduced depressive-like behaviors and lowered levels of neuroinflammation (search). Importantly, it achieved these effects without affecting locomotor activity, suggesting that the behavioral improvements were not simply due to increased movement or stimulation.
Distinct Binding Profile
Further analysis revealed that compound #15 (search) binds to the NK1 receptor in a way that differs from earlier drugs, supporting the idea that structural diversity can meaningfully alter biological outcomes. This distinct interaction profile may explain why the new compounds succeeded where previous NK1R (search) antagonists failed.
"Our findings suggest that the structurally distinct antagonists identified in this study exhibit antidepressant-like effects, providing renewed evidence for further exploration of NK1R (search) antagonism as a therapeutic strategy for MDD," said Professor Hong-Rae Kim, assistant professor in medicinal chemistry at Korea University.
Implications for Treatment-Resistant Depression
The findings may have implications beyond standard depression (search) treatment. Increasing evidence suggests that inflammation contributes to poor antidepressant response in a subset of patients. Structurally novel NK1R (search) antagonists could therefore be explored as treatments for inflammation-associated or treatment-resistant forms of depression.
"Our results provide a foundation for optimizing NK1R (search) antagonists and underscore the importance of structural diversity, which could lead to new therapeutic options in treatment-resistant or inflammation-associated depression (search)," Professor Kim concluded.
Broader Strategy for Drug Development
Beyond NK1R (search) specifically, the study highlights a broader strategy in drug development: revisiting previously abandoned targets using modern computational tools and rigorous biological validation. As this research demonstrates, past failures may sometimes reflect limitations in chemical design rather than flaws in the underlying biology, potentially opening new therapeutic possibilities for conditions where treatment options remain limited.